[go: up one dir, main page]

HK1167388A1 - Anticancer compound and pharmaceutical composition containing the same - Google Patents

Anticancer compound and pharmaceutical composition containing the same

Info

Publication number
HK1167388A1
HK1167388A1 HK12108002.5A HK12108002A HK1167388A1 HK 1167388 A1 HK1167388 A1 HK 1167388A1 HK 12108002 A HK12108002 A HK 12108002A HK 1167388 A1 HK1167388 A1 HK 1167388A1
Authority
HK
Hong Kong
Prior art keywords
compound
same
pharmaceutical composition
composition containing
anticancer compound
Prior art date
Application number
HK12108002.5A
Other languages
English (en)
Inventor
Jean-Christophe Carry
Michel Cheve
Francois Clerc
Cecile Combeau
Sylvie Gontier
Alain Krick
Sylvette Lachaud
Laurent Schio
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1167388A1 publication Critical patent/HK1167388A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12108002.5A 2009-05-18 2012-08-15 Anticancer compound and pharmaceutical composition containing the same HK1167388A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant
PCT/FR2010/050948 WO2010133794A1 (fr) 2009-05-18 2010-05-17 Compose anticancéreux et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
HK1167388A1 true HK1167388A1 (en) 2012-11-30

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12108002.5A HK1167388A1 (en) 2009-05-18 2012-08-15 Anticancer compound and pharmaceutical composition containing the same

Country Status (35)

Country Link
US (2) US9073917B2 (el)
EP (1) EP2432766B1 (el)
JP (1) JP5656981B2 (el)
KR (1) KR20120032483A (el)
CN (1) CN102459193B (el)
AR (1) AR076686A1 (el)
AU (1) AU2010251013B2 (el)
BR (1) BRPI1012201A2 (el)
CA (1) CA2762233C (el)
CL (1) CL2011002930A1 (el)
CO (1) CO6400138A2 (el)
CY (1) CY1114850T1 (el)
DK (1) DK2432766T3 (el)
EA (1) EA021084B1 (el)
ES (1) ES2430989T3 (el)
FR (1) FR2945535B1 (el)
HK (1) HK1167388A1 (el)
HR (1) HRP20130959T1 (el)
IL (1) IL216361A0 (el)
JO (1) JO2852B1 (el)
MA (1) MA33356B1 (el)
ME (1) ME01542B (el)
MX (1) MX2011012356A (el)
MY (1) MY152995A (el)
NZ (1) NZ596464A (el)
PL (1) PL2432766T3 (el)
PT (1) PT2432766E (el)
RS (1) RS53002B (el)
SG (1) SG176169A1 (el)
SI (1) SI2432766T1 (el)
SM (1) SMT201400005B (el)
TW (1) TWI441822B (el)
UY (1) UY32644A (el)
WO (1) WO2010133794A1 (el)
ZA (1) ZA201108447B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
EP2909204B1 (en) 2012-10-12 2018-12-05 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
EP3164388A1 (en) 2014-07-01 2017-05-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
AU2018249558A1 (en) 2017-04-05 2019-11-07 Biogen Ma Inc. Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003529552A (ja) 1999-11-19 2003-10-07 アボット・ラボラトリーズ 三環性ジヒドロピリミジンカリウムチャンネル開口剤
CA2437215A1 (en) 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005016245A2 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
ES2339676T3 (es) * 2005-07-20 2010-05-24 Aventis Pharma S.A. Heterociclicos condensados con 1,4-dihidropiridina, procedimiento par a prepararlos, uso y composiciones que los contienen.
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
WO2010133794A1 (fr) 2010-11-25
FR2945535A1 (fr) 2010-11-19
US9221817B2 (en) 2015-12-29
DK2432766T3 (da) 2013-10-28
CN102459193B (zh) 2014-08-27
AU2010251013B2 (en) 2015-08-20
BRPI1012201A2 (pt) 2016-04-05
SG176169A1 (en) 2011-12-29
ME01542B (me) 2014-04-20
JP2012527436A (ja) 2012-11-08
PL2432766T3 (pl) 2013-12-31
CN102459193A (zh) 2012-05-16
KR20120032483A (ko) 2012-04-05
EA021084B1 (ru) 2015-04-30
ZA201108447B (en) 2013-01-30
EA201171429A1 (ru) 2012-05-30
CL2011002930A1 (es) 2012-06-29
AU2010251013A1 (en) 2011-12-08
UY32644A (es) 2010-12-31
HRP20130959T1 (hr) 2013-11-22
JP5656981B2 (ja) 2015-01-21
NZ596464A (en) 2014-01-31
PT2432766E (pt) 2013-10-23
EP2432766B1 (fr) 2013-07-17
CO6400138A2 (es) 2012-03-15
SI2432766T1 (sl) 2013-11-29
RS53002B (en) 2014-04-30
CA2762233C (fr) 2017-11-28
TWI441822B (zh) 2014-06-21
JO2852B1 (en) 2015-03-15
US20150266877A1 (en) 2015-09-24
MY152995A (en) 2014-12-31
CA2762233A1 (fr) 2010-11-25
FR2945535B1 (fr) 2011-06-10
MX2011012356A (es) 2011-12-14
AR076686A1 (es) 2011-06-29
EP2432766A1 (fr) 2012-03-28
US20120220621A1 (en) 2012-08-30
CY1114850T1 (el) 2016-12-14
ES2430989T3 (es) 2013-11-22
US9073917B2 (en) 2015-07-07
MA33356B1 (fr) 2012-06-01
SMT201400005B (it) 2014-03-07
IL216361A0 (en) 2012-01-31
TW201100418A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
HK1167388A1 (en) Anticancer compound and pharmaceutical composition containing the same
UA94052C2 (uk) Похідні піридазину
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
TW200608972A (en) Aryl-pyridine derivatives
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
GB0114286D0 (en) Nucleoside Derivatives
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
GEP20125459B (en) Compounds for inhibiting mitotic progression
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2010005824A (es) Derivados de aminotiazol.
IN2012DN03337A (el)
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2009003169A (es) Derivados de sulfonamida.
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
IL191670A0 (en) Compounds for the inhibition of apoptosis
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TH135249A (th) สารประกอบตัวยับยั้งออโรราต้านมะเร็งและองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว, กระบวนการและอินเทอร์มิเดียทสำหรับการเตรียมสารเหล่านั้น
EP1889831A3 (en) Diazenedicarboxamides as inhibitors of D-alanine: D-alanine ligase (Ddl)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170517